Immunosuppression Strategies in Simultaneous Organ Transplant

Posted on June 10, 2021
Danielle Kovac, PharmD and Douglas Jennings, PharmD

Speakers:

Danielle Kovac, PharmD 
Liver and Intestinal Transplantation Clinical Pharmacist
New York-Presbyterian Hospital
Columbia University Irving Medical Center

Douglas Jennings, PharmD, FACC, FAHA, FCCP, FHFSA, BCPS
Associate Professor of Pharmacy and Clinical Pharmacist
New York-Presbyterian Hospital
Columbia University Irving Medical Center

A Knowledge-Based Activity
ACPE UAN# 0016-9999-21-047-L01-P
0.75 contact hours (0.075 CEUs)
0.75 contact hour CNE

Learning Objectives:

  • Describe the pathophysiologic features and comorbid conditions leading to simultaneous organ transplant
  • Identify key immunologic characteristics pertaining to simultaneous organ transplantation
  • Construct evidence-based recommendations for induction and maintenance immunosuppression in simultaneous organ transplant

Disclosures:

Dr. Muran is a consultant for Veloxis. Dr. Shields is co-investigator on a study funded by Bristol Myers Squibb. All of the other speakers, planning committee members, and reviewers who contributed to this activity have no relevant financial relationships with ineligible companies to disclose.

Modified on July 14, 2021